Bill Detail
H.R. 1414
Congress: 119
Title
Cameron’s Law
Summary
Cameron's Law This bill increases the orphan drug tax credit to 50% (from 25%) of qualified clinical testing expenses paid or incurred in the development of drugs to treat certain rare diseases or conditions. As background, the Tax Cuts and Jobs Act reduced the orphan drug tax credit (for tax years after 2017) to 25% of qualified clinical testing expenses (e.g., wages, supplies, and certain contract expenses) paid or incurred in the development of drugs to treat certain rare diseases or conditions. For 2017 and prior tax years, the orphan tax credit was 50% of such expenses paid or incurred.
Sponsor
Rep. Josh Gottheimer [D-NJ-5]
Status
Referred to the House Committee on Ways and Means.
Status as of Jul 27, 8:37 PM · synced 17d ago
Introduced
2025-02-18
Data source mode: congress-gov
Bill Engagement
Cameron's Law This bill increases the orphan drug tax credit to 50% (from 25%) of qualified clinical testing expenses paid or incurred in the development of drugs to treat certa…
Lobbyists on the case
- The Washington Tax & Public Policy Group1 filing · 3 lobs
- Gregory Nickerson2026 Q1The Washington Tax & Public Policy Group · Tax Counsel, Ways and Means Committee; Staff Director, Ways and Means Select Revenue Measures Sub…
- James Pedrotti2026 Q1The Washington Tax & Public Policy Group · Legislative Correspondent, Legislative Assistant, Senior Legislative Assistant, Legislative Direc…
Prepared intelligence brief
Put this record in the joined picture.
Unlock every organization and lobbyist filing on this bill, the complete event and issue map, private team positions, and recurring movement alerts across the portfolio.